Your browser is no longer supported. Please, upgrade your browser.
InMed Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own0.78% Shs Outstand8.05M Perf Week-16.24%
Market Cap18.64M Forward P/E- EPS next Y-1.12 Insider Trans0.00% Shs Float8.01M Perf Month-25.21%
Income-8.60M PEG- EPS next Q-0.34 Inst Own6.50% Short Float1.17% Perf Quarter-36.59%
Sales- P/S- EPS this Y11.00% Inst Trans0.76% Short Ratio1.35 Perf Half Y-56.60%
Book/sh1.38 P/B1.64 EPS next Y- ROA-97.20% Target Price- Perf Year-52.51%
Cash/sh1.16 P/C1.96 EPS next 5Y- ROE-132.90% 52W Range2.38 - 8.94 Perf YTD-31.00%
Dividend- P/FCF- EPS past 5Y5.90% ROI- 52W High-74.61% Beta1.45
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low-4.62% ATR0.23
Employees13 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)34.00 Volatility10.14% 8.12%
OptionableNo Debt/Eq0.03 EPS Q/Q-6.00% Profit Margin- Rel Volume3.21 Prev Close2.76
ShortableYes LT Debt/Eq0.02 EarningsMay 13 Payout- Avg Volume69.08K Price2.27
Recom- SMA20-16.80% SMA50-20.33% SMA200-36.02% Volume221,446 Change-17.75%
Jul-02-21 04:15PM  
Jun-29-21 07:00AM  
Jun-28-21 08:35AM  
Jun-22-21 12:29PM  
Jun-21-21 08:35AM  
Jun-17-21 07:30AM  
Jun-15-21 06:41AM  
Jun-09-21 11:30AM  
May-13-21 09:15AM  
May-06-21 07:30AM  
May-04-21 07:30AM  
Apr-28-21 07:30AM  
Apr-27-21 07:30AM  
Apr-26-21 07:30AM  
Mar-17-21 02:49PM  
Mar-03-21 06:00PM  
Feb-26-21 08:00AM  
Feb-16-21 07:30AM  
Feb-11-21 09:30AM  
Feb-08-21 07:04AM  
Feb-05-21 09:00PM  
Feb-02-21 07:00AM  
Feb-01-21 05:00AM  
Jan-26-21 08:00AM  
Jan-19-21 02:00PM  
Jan-18-21 07:00AM  
Jan-08-21 07:30AM  
Jan-05-21 04:52PM  
Dec-11-20 07:00AM  
Nov-25-20 07:30AM  
Nov-24-20 08:00PM  
Nov-18-20 07:30AM  
Nov-17-20 06:00AM  
Nov-16-20 11:42AM  
Nov-13-20 07:30AM  
Nov-12-20 09:10AM  
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.